Nanobiotix Shares Surge by 10.30% Defying a Plummeting CAC 40
This Monday at midday, Nanobiotix recorded a 10.3% increase, bringing its share price to 31.60 euros, up from last Friday's close at 28.65 euros. This surge is part of a pronounced upward trend, with a gain of 18% over seven days and nearly 887% over a year. The stock is moving against the current of a sharply declining Parisian market, with the CAC 40 losing more than 2% during the session.
Breaking the Upper Bollinger Band
This Monday, Nanobiotix's share price crossed its upper Bollinger band and settled above the 31 euros mark. This breakthrough indicates an acceleration of the buying trend beyond the usual statistical fluctuation zone. The Relative Strength Index (RSI), which measures the speed and magnitude of price movements, stands at 80, well above the conventional overbought threshold of 70. This level signals that the stock has experienced a very rapid upward movement, which historically could precede a consolidation phase. The nearest resistance was at 28.90 euros, a level that the stock has clearly exceeded during the session. The 20, 50, and 200-day moving averages — at 23.28, 20.27, and 13.46 euros respectively — all remain significantly distant from the current price, confirming the magnitude of the bullish shift accumulated in recent weeks. Over three months, the increase reaches 66.39%.
Contrasting Performance in Global Market Downturn
Nanobiotix's performance today starkly contrasts with the general tone of the equity markets. The CAC 40 is down 2.03% in the session, while the SBF 120 loses 2.02%. In Asia, the Nikkei 225 closed down 5.20% and the Hang Seng ended down 1.35%. The FTSE 100 is down 1.42% in London. This context of generalized correction is juxtaposed with a sharply rising VIX index: the S&P 500's implied volatility indicator, recorded last Thursday, stood at 23.75 points, up 12.29% from the previous day, reflecting increased nervousness in global markets. Nanobiotix's beta, measured at 0.10, indicates that the stock historically moves largely independently of major indices. Its recent trajectory illustrates this: while financial markets globally are posting significant losses, the Parisian biotech continues its ascent with no apparent correlation to the prevailing downward movement. This decoupling reminds us that the stock's valuation depends primarily on company-specific catalysts, in a sector where clinical and regulatory advances often outweigh macroeconomic conditions.
